The U.S. Food and Drug Administration (FDA) has designated 4D Path’s software a breakthrough device as a possible way to achieve a faster and more accurate breast cancer diagnosis based on tissue taken in a breast biopsy or resection. Named 4D Q-plasia OncoReader Breast, the software is intended to aid doctors in evaluating biopsies and resections (tumors that are surgically removed), and in achieving a more accurate diagnosis. “We are thrilled that the FDA has recognized the potential of our…
You must be logged in to read/download the full post.
The post FDA Gives Breakthrough Device Status to 4D Path’s Breast Cancer Diagnostic Platform appeared first on BioNewsFeeds.